Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:ATRANASDAQ:CRTXNASDAQ:DBVTNASDAQ:MGTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$9.39-7.9%$15.62$7.10▼$29.70$194.84M0.84249,470 shs838,744 shsATRAAtara Biotherapeutics$0.70-1.4%$0.72$0.20▼$3.02$85.31M0.691.04 million shs865,826 shsCRTXCortexyme$1.03-2.8%$1.18$1.78▼$40.66$31.06M1.4620,672 shs93,060 shsDBVTDBV Technologies$0.69$0.78$0.65▼$2.37$133.27M0.7544,818 shs40,904 shsMGTXMeiraGTx$4.71-3.1%$5.85$3.49▼$8.35$312.10M1.29150,163 shs121,649 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-7.85%-15.78%-33.64%-0.05%+17.13%ATRAAtara Biotherapeutics-2.08%+1.17%+5.87%+16.19%-74.37%CRTXCortexyme-4.50%0.00%-6.19%-18.46%-31.61%DBVTDBV Technologies+3.68%-0.09%-11.19%-22.97%-56.64%MGTXMeiraGTx-3.09%-5.99%-23.54%-30.22%-12.45%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies3.7876 of 5 stars3.51.00.04.82.42.50.0ATRAAtara Biotherapeutics3.7569 of 5 stars3.01.00.04.72.62.50.6CRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/ADBVTDBV Technologies2.2343 of 5 stars3.23.00.00.00.03.31.3MGTXMeiraGTx4.2454 of 5 stars3.53.00.04.82.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67269.19% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,901.14% UpsideCRTXCortexymeN/AN/AN/AN/ADBVTDBV Technologies2.33Hold$5.00625.22% UpsideMGTXMeiraGTx3.00Buy$25.67444.94% UpsideCurrent Analyst RatingsLatest ADVM, MGTX, ATRA, DBVT, and CRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M54.12N/AN/A$8.26 per share1.14ATRAAtara Biotherapeutics$8.57M9.75N/AN/A($0.97) per share-0.72CRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/ADBVTDBV Technologies$15.73M8.45N/AN/A$0.73 per share0.94MGTXMeiraGTx$14.02M21.57N/AN/A$2.17 per share2.17Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)CRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/ADBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.23N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)Latest ADVM, MGTX, ATRA, DBVT, and CRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13ATRAAtara BiotherapeuticsN/A0.720.65CRTXCortexymeN/A9.929.92DBVTDBV TechnologiesN/A4.264.26MGTXMeiraGTx0.622.382.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ATRAAtara Biotherapeutics70.90%CRTXCortexyme63.18%DBVTDBV Technologies71.74%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%ATRAAtara Biotherapeutics4.50%CRTXCortexyme27.90%DBVTDBV Technologies0.71%MGTXMeiraGTx9.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.75 million19.66 millionOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableADVM, MGTX, ATRA, DBVT, and CRTX HeadlinesSourceHeadlineMeiraGTx Holdings plc (NASDAQ:MGTX): Is Breakeven Near?finance.yahoo.com - April 25 at 10:32 AMMeiraGTx to Participate in Upcoming Investor Conferencesglobenewswire.com - April 24 at 4:30 PMMeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conferenceglobenewswire.com - April 18 at 4:30 PMMGTX Apr 2024 12.500 callfinance.yahoo.com - March 17 at 2:29 AMBuy Rating Affirmed: Meiragtx Holdings’ Promising Pipeline and Strategic Partnerships Set Stage for Growthmarkets.businessinsider.com - March 15 at 11:23 PMMGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 14 at 10:03 PMRecap: MeiraGTx Hldgs Q4 Earningsbenzinga.com - March 14 at 8:49 PMMeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023hk.finance.yahoo.com - March 14 at 3:48 PMMeira Retreats on Financial Figuresbaystreet.ca - March 14 at 10:48 AMMeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimateszacks.com - March 14 at 10:46 AMMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updatesglobenewswire.com - March 14 at 8:30 AMMeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%finance.yahoo.com - February 26 at 1:35 PMMGTX Mar 2024 12.500 callfinance.yahoo.com - February 17 at 10:20 AMMeiraGTx: Bota-Vec Program Advancing With Milestones Being Metseekingalpha.com - February 16 at 6:38 PMMeiraGTx Holdings PLC MGTXmorningstar.com - February 15 at 8:13 PMMeiraGTx Holdings: Other Events, Financial Statements And Exhibitscbonds.com - February 15 at 10:12 AMMeiraGTx receives $50 million milestone payment from Janssenthepharmaletter.com - February 14 at 7:52 AMMeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticalsfinance.yahoo.com - February 13 at 10:56 AMWall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Betfinance.yahoo.com - January 10 at 4:20 PMMeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisionsfinance.yahoo.com - January 10 at 11:20 AMWall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Tradefinance.yahoo.com - December 25 at 1:49 PMMeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest Reportbenzinga.com - December 24 at 8:21 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)markets.businessinsider.com - December 23 at 12:00 AMMeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.CortexymeNASDAQ:CRTXCortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.